Peptides: What You Need to Know
If you spend time on social media or attend wellness, longevity, fitness, or health-care conferences, you have probably heard about peptides.
They are often promoted as tools to heal injuries, reverse aging, improve sleep and energy, increase muscle, restore libido, improve body composition, or accelerate weight loss.
Some peptide-based medicines are important, rigorously studied treatments.
Others are experimental compounds being marketed far ahead of the human evidence.
The word peptide alone does not tell you whether a product is effective, safe, regulated, or appropriate for you.
The key is to separate legitimate, indication-specific medical treatment from confident marketing claims that go beyond the data.
What Is a Peptide?
A peptide is a relatively short chain of amino acids, the building blocks of proteins.
Many peptides occur naturally in the body and act as signaling molecules, hormones, or neurotransmitters.
But “peptide” is a chemical description, not a seal of approval. For example:
Insulin is a peptide hormone and a life-saving, FDA-approved treatment for diabetes.
Teriparatide is a peptide-based medication used for certain people at high risk of osteoporotic fracture.
Semaglutide and tirzepatide are peptide-based medications used for specific diabetes, weight-management, and in some cases, cardiovascular-risk indications.
BPC-157 is widely promoted online for injury recovery but is not FDA-approved for human use.
In other words: Each peptide needs to be evaluated on its own evidence, approved use, formulation, dose, and risk profile.
FDA-Approved Peptide Medicines
FDA approval means the agency has reviewed evidence supporting a drug’s safety and effectiveness for a specific indication. It does not mean a medication is risk-free, appropriate for everyone, or proven for every use discussed online.
The FDA-approved label matters. It defines the population studied, the condition being treated, how the medication is used, major warnings, contraindications, and known adverse effects.
Below are several examples of peptide-based medications that have FDA-approved uses.
Peptide-based medicine | FDA-approved use, simplified | Important safety considerations | |
Semaglutide: Ozempic, Wegovy, Rybelsus | Type 2 diabetes for specific products; chronic weight management for Wegovy in eligible patients; Wegovy also has an indication to reduce cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity | Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are common. The label carries a boxed warning because thyroid C-cell tumors occurred in rodents; whether this applies to humans is unknown. It is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis and gallbladder disease are among other important warnings. | |
Tirzepatide: Mounjaro, Zepbound | Type 2 diabetes for Mounjaro; chronic weight management for Zepbound in eligible adults | Gastrointestinal symptoms are common, especially during dose escalation. The boxed warning is based on thyroid C-cell tumors in rats; human relevance is unknown. Other important warnings include pancreatitis and acute gallbladder disease. | |
Bremelanotide: Vyleesi | Acquired, generalized hypoactive sexual desire disorder in premenopausal women | Nausea is common. It can temporarily raise blood pressure and lower heart rate, so it is not appropriate for everyone. It is not approved for postmenopausal women, men, or general sexual-performance enhancement. | |
Tesamorelin: Egrifta | Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, a condition involving abnormal fat distribution | Injection-site reactions, joint pain, fluid retention, and changes in glucose tolerance can occur. It is not approved as a general weight-loss, muscle-building, or anti-aging treatment. | |
Insulin and insulin analogs | Diabetes management | Hypoglycemia is the major risk. Insulin dosing, meal timing, physical activity, glucose monitoring, and other medications all require individualized clinical management. | |
Teriparatide: Forteo | Treatment of osteoporosis in postmenopausal women and other specified people at high risk for fracture | Teriparatide is a parathyroid-hormone analog that stimulates bone formation in an appropriate clinical setting. It is not a general “bone optimization” treatment. In pivotal research, it reduced vertebral and nonvertebral fracture risk in women with osteoporosis. |
This is not an exhaustive list.
Peptide-based medications are also used in fertility treatment, endocrine disorders, gastrointestinal disease, diabetes insipidus, cancer care, and other specialized medical settings.
The important point is that these treatments were studied and they reviewed a particular formulation, dose, indication, and benefit-risk profile.
The “Wellness Peptides”: What Data Exist?
Many peptides marketed through longevity, recovery, performance, and body-composition clinics are not FDA-approved for the claims made about them.
That does not mean every one has no research behind it.
It means the available evidence often falls short of the standard needed to establish a safe dose, meaningful clinical benefit, and long-term safety for the way these compounds are being marketed.
A useful distinction: a study showing that a compound changes a hormone level, affects cells in a dish, or improves an outcome in rodents is not the same as showing that it safely improves health, recovery, body composition, sleep, or longevity in humans.
Peptide | Common marketing claims | What human or preclinical data show | What is not established / key limitations |
BPC-157 | Faster recovery from tendon, ligament, muscle, or joint injuries; wound healing; gastrointestinal healing | There is substantial preclinical and animal literature suggesting effects on tissue healing and angiogenesis-related pathways. Human data are extremely limited: a small number of pilot studies or uncontrolled reports have been described, including work involving knee pain, interstitial cystitis, and short-term intravenous exposure. A Phase 1 safety/pharmacokinetic trial in healthy volunteers was registered but later canceled without published results. | No large, well-controlled randomized human trial establish that BPC-157 heals tendon, ligament, muscle, or joint injuries. There is no established dose, route, treatment duration, or long-term safety profile. FDA has stated that available clinical safety information is insufficient to characterize its safety profile. It is not FDA-approved and is prohibited in sport under WADA’s category for non-approved substances. |
CJC-1295 | Increased growth hormone; improved sleep, recovery, muscle gain, fat loss, and anti-aging effects | A small early human study found that CJC-1295 increased circulating growth hormone by roughly 2- to 10-fold for six days or longer and increased IGF-1 by roughly 1.5- to 3-fold for 9–11 days after a single injection. Short-term study participants did not report serious adverse reactions. | Raising growth hormone and IGF-1 is a biological effect and not evidence of improved muscle, recovery, sleep, body composition, healthspan, or lifespan. Large trials, long-term follow-up, and trials establishing benefits and risks in healthy adults are lacking. There is no adequate human evidence on long-term metabolic, cardiovascular, or cancer-related outcomes. |
Ipamorelin | Growth-hormone support; sleep, recovery, body composition, muscle gain, fat loss, and anti-aging | Ipamorelin is a ghrelin-receptor agonist/growth-hormone secretagogue. Human randomized studies have examined it in narrow medical or research settings, including postoperative ileus after bowel surgery and not as a longevity or physique treatment. | Those studies do not show that ipamorelin improves aging, athletic performance, muscle mass, body fat, sleep, injury healing, or longevity in healthy adults. Long-term safety data for wellness use are limited, particularly regarding chronic manipulation of growth-hormone/IGF-1 signaling. |
CJC-1295 plus ipamorelin | “Stacked” for synergistic growth hormone release, lean mass, sleep, injury repair, and fat loss | The rationale is pharmacologic: CJC-1295 acts through growth-hormone–releasing-hormone pathways and ipamorelin acts through ghrelin-receptor signaling. Available data on CJC-1295 alone demonstrate hormone changes; this does not validate a combined wellness protocol. | There are no robust clinical trials establishing that this combination is safe or effective for anti-aging, body composition, sleep, exercise recovery, injury healing, or general health. Combining compounds can create different effects and risks than studying either one alone. |
TB-500 / thymosin beta-4–related products | Injury recovery, tendon and muscle healing, inflammation reduction, faster rehabilitation | Thymosin beta-4 has preclinical research involving cell migration, inflammation, angiogenesis, and tissue-repair pathways. Some clinical research has evaluated pharmaceutical forms of thymosin beta-4 for highly specific conditions, such as corneal healing, rather than sports injuries or generalized recovery. | There is no adequate clinical evidence that products sold as TB-500 safely accelerate healing of tendons, ligaments, muscle injuries, or orthopedic conditions in healthy adults. “TB-500” products may not be equivalent to studied thymosin beta-4 formulations. Product identity, purity, dose, and sterility are additional concerns. |
Thymosin alpha-1 | Immune enhancement, fewer infections, improved recovery, cancer support, and longevity | Thymosin alpha-1 has more human research than many peptides in this table. Trials and systematic reviews have examined it in specific clinical contexts, including chronic viral hepatitis, sepsis, cancer-related settings, and vaccine response. Some analyses suggest possible benefits in selected settings, but results are mixed and depend on the condition and study quality. | Thymosin alpha-1 is not FDA-approved in the United States. Existing disease-specific studies do not establish that it safely “boosts immunity,” prevents routine infections, improves wellness, or extends lifespan in healthy people. Larger and higher-quality trials have not consistently confirmed benefit for some proposed uses. |
Epitalon / Epithalon | Telomere restoration, improved sleep or circadian rhythm, “cellular rejuvenation,” lifespan extension | Laboratory studies in cultured human cells suggest epitalon can influence telomerase activity and telomere length. Animal and observational research has generated hypotheses about aging-related effects. | Cell-culture findings are not proof that epitalon lengthens telomeres, slows aging, prevents disease, or extends lifespan in people. No well-controlled randomized human clinical trial has demonstrated telomere-lengthening, healthspan, or lifespan benefit. Long-term human safety is not established. |
Sermorelin | Growth-hormone support, sleep, body composition, energy, and anti-aging | Sermorelin is a growth-hormone–releasing hormone analog with a prior U.S. regulatory history for pediatric growth-hormone deficiency. Its ability to stimulate growth-hormone secretion is biologically established. | It is not a currently FDA-approved anti-aging, muscle-building, sleep, or body-composition medication. A prior pediatric indication does not validate its use for adult wellness. There is insufficient high-quality evidence that it improves age-related symptoms or outcomes in healthy adults. |
MOTS-c | Improved mitochondrial function, endurance, metabolic health, fat loss, exercise performance, and healthy aging | MOTS-c is a mitochondria-derived peptide with compelling early laboratory and animal research related to metabolism and exercise physiology. Human observational research has examined naturally occurring MOTS-c levels and genetic variation. | Human evidence does not establish that injected or supplemented MOTS-c improves fitness, insulin sensitivity, weight, muscle function, or longevity. There is no established therapeutic dose, route, duration, or long-term human safety profile for wellness use. |
KPV | Gut health, inflammatory bowel symptoms, skin inflammation, immune modulation, and healing | KPV is a short fragment related to alpha-melanocyte–stimulating hormone. It has preclinical research involving inflammatory pathways and animal models of colitis and skin inflammation. | Preclinical anti-inflammatory findings do not establish clinical effectiveness for inflammatory bowel disease, “leaky gut,” eczema, acne, psoriasis, or systemic inflammation. High-quality human clinical trials and long-term safety data are lacking. |
GHK-Cu, including injectable products | Collagen production, skin repair, hair growth, wound healing, and anti-aging | GHK-Cu has laboratory and topical cosmetic research involving collagen-related signaling, skin appearance, and wound-healing mechanisms. Some topical formulations may have limited human cosmetic data. | Evidence for injected GHK-Cu is far less established than evidence for topical cosmetic use. No FDA-approved injectable GHK-Cu product exists for skin rejuvenation, hair growth, anti-aging, or systemic wellness. Injectable dosing, systemic effects, and long-term safety are not established. |
Semax and Selank | Anxiety relief, improved focus, memory, mood, stress resilience, neuroprotection, and cognitive enhancement. | These peptides have been studied primarily in limited regional research programs and experimental settings. The published evidence base is smaller and less independently replicated than would be needed for broad clinical claims. | They are not FDA-approved in the United States. There is not enough high-quality, independently replicated human evidence to establish safety or effectiveness for anxiety, ADHD, depression, cognitive enhancement, or neuroprotection. |
Kisspeptin-10 | Libido, fertility, reproductive hormone support, and testosterone or estrogen “optimization”. | Kisspeptin is a genuine reproductive-hormone signaling pathway. Small human studies have shown that kisspeptin can stimulate reproductive hormone release in controlled research settings, and it has been investigated in infertility research. | A short-term hormonal response does not establish safe or effective treatment for low libido, menopause symptoms, infertility, testosterone optimization, or general wellness. Use outside of research or specialized reproductive-endocrinology care is not supported by an FDA-approved indication. |
AOD-9604 | Fat loss, appetite control, metabolic health, and “HGH benefits without HGH risks” | AOD-9604 is a growth-hormone fragment studied for obesity and metabolic effects. Clinical development did not establish it as an approved obesity treatment. | It is not FDA-approved for weight loss. There is no robust evidence that it produces clinically meaningful, sustained fat loss or improves metabolic health in the way marketing claims often imply. |
Melanotan II | Tanning, libido enhancement, erectile function, appetite reduction, and body-composition effects | Melanotan II activates melanocortin pathways, which helps explain effects such as skin darkening, nausea, and sexual effects. Its pharmacology is real, but the product is not an FDA-approved tanning or wellness treatment. | It is not FDA-approved. Unregulated injectable products create concerns about dose accuracy, sterility, contaminants, blood-pressure effects, nausea, and changing or darkening moles or skin lesions. It should not be used as a substitute for sun protection or dermatologic surveillance. |
LL-37 | Immune support, antimicrobial activity, wound healing, gut repair, and biofilm disruption. | LL-37 is an endogenous antimicrobial peptide with extensive laboratory and preclinical research. Its immune effects are complex and context dependent. | Antimicrobial activity in a laboratory setting does not establish that injected or compounded LL-37 safely treats infections, Lyme disease, “chronic inflammation,” gut conditions, or wounds in people. Human clinical evidence and long-term safety for these uses are inadequate. |
DSIP | Sleep, stress reduction, pain relief, and hormonal balance. | Delta sleep-inducing peptide has a long history of experimental interest, but the published research is limited and does not provide a modern, robust clinical evidence base for insomnia or stress management. | It is not FDA-approved for sleep. There is no high-quality evidence establishing an effective dose, durable improvement in insomnia, or long-term safety in people using it for wellness. |
Compounded Peptides Are Not FDA-Approved
The word “compounded” can sound reassuring, especially when a product is prescribed through a medical practice or prepared by a pharmacy.
But it is important to understand what this means.
A compounded medication is a drug prepared by a pharmacy for an individual patient rather than manufactured and sold as an FDA-approved commercial product.
Compounding can serve a legitimate medical purpose.
For example, a patient may need a different dose, a liquid rather than a tablet, an allergen-free formulation, or a medication that is temporarily unavailable in its FDA-approved form.
However, compounded medications are not FDA-approved.
Unlike an FDA-approved drug, they generally have not gone through FDA premarket review for that specific product’s:
Safety
Effectiveness
Dose and consistency
Purity and sterility
Manufacturing quality
That does not mean every compounded medication is unsafe or inappropriate.
It means that “compounded” should not be confused with “FDA-approved,” and it should not be used as proof that a peptide has been shown to work for a particular goal.
When considering a compounded peptide, useful questions to ask include:
Is there an FDA-approved version of this medication available?
What specific medical condition is this intended to treat?
Why is a compounded product being recommended instead of an FDA-approved option?
What are the known risks, side effects, and monitoring requirements?
Who will manage dosing, follow-up, and any side effects?
The goal is not to assume that compounded medicine is wrong, especially when prescribed by a physician.
The Bottom Line
Peptides are not one category of treatment.
They range from long-established, life-saving therapies such as insulin to experimental compounds with little reliable human data.
If considering a peptide, ask the appropraite questions:
“What data are available for this peptide?"
"What outcomes defined efficacy for this peptide?"
"What does the safety profile look like for this peptide?"
Whether it is FDA approved or not, the quality of the data would be the justification for putting it into your body.
As a health coach, my role is to help people evaluate health claims, understand the evidence, and prepare for a better informed conversation with their prescribing clinician.
If you are taking a peptide medication or considering one, consult a qualified licensed physician first to ensure there are no safety concerns given your medical history.
Book your optimal health strategy session today!
References
U.S. Food and Drug Administration. (2025). Wegovy (semaglutide) injection: Prescribing information.Supports Wegovy’s indications, the rodent thyroid C-cell tumor boxed warning, contraindications, gastrointestinal adverse effects, pancreatitis, and gallbladder warnings.accessdata.fda
U.S. Food and Drug Administration. (2025). Mounjaro (tirzepatide) injection: Prescribing information.Supports Mounjaro’s type 2 diabetes indication, tirzepatide’s boxed warning, and key adverse-effect and safety information.accessdata.fda
U.S. Food and Drug Administration. (2023). FDA approves new medication for chronic weight management.Supports Zepbound’s FDA approval and its use for chronic weight management in eligible adults.fda
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenblit, P. D., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.https://doi.org/10.1056/NEJMoa2032183Supports pivotal clinical efficacy and safety data for semaglutide 2.4 mg in chronic weight management.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.https://doi.org/10.1056/NEJMoa2206038Supports pivotal clinical efficacy and safety data for tirzepatide in chronic weight management.
U.S. Food and Drug Administration. (2019). Vyleesi (bremelanotide) injection: Prescribing information.Supports Vyleesi’s indication for acquired, generalized hypoactive sexual desire disorder in premenopausal women, along with nausea, blood-pressure effects, and contraindications.accessdata.fda
Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Simon, J. A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899–908.https://doi.org/10.1097/AOG.0000000000003500Supports bremelanotide’s clinical-trial evidence in premenopausal women with acquired, generalized HSDD.
Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, B., Brown, S. J., Richmond, G., Fessel, J., Turner, R., Grinspoon, S., & the Canadian HIV Lipodystrophy Study Group. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.https://doi.org/10.1056/NEJMoa070484Supports tesamorelin’s evidence for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J. Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., Mitlak, B. H., & the Osteoporosis Prevention and Treatment Study Group. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344(19), 1434–1441.https://doi.org/10.1056/NEJM200105103441904Supports teriparatide’s effects on bone mineral density and vertebral and nonvertebral fracture risk in postmenopausal osteoporosis.
U.S. Food and Drug Administration. (2020). Forteo (teriparatide) injection: Prescribing information.Supports FDA-approved uses, contraindications, warnings, and limitations for teriparatide.accessdata.fda
U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee. (2026). Briefing document for BPC-157-related bulk drug substances: BPC-157 free base and BPC-157 acetate.Supports the statement that FDA found available clinical safety information insufficient to characterize BPC-157’s safety profile. It is also a key source for the difference between scientific evidence review and compounding-policy decisions.fda+1
ClinicalTrials.gov. (2015). PCO-02: Safety and pharmacokinetics trial of BPC-157 in healthy volunteers(NCT02637284).https://clinicaltrials.gov/study/NCT02637284Supports the statement that an early BPC-157 human safety/pharmacokinetic trial was registered. It should not be cited as evidence that BPC-157 works, because publicly available efficacy results have not been published.clinicaltrials
U.S. Anti-Doping Agency, Operation Supplement Safety. (2025). BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products.Supports BPC-157’s unapproved status and its prohibition in sport under WADA’s category for non-approved substances.opss
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.https://doi.org/10.1210/jc.2005-1536Supports the limited human pharmacology evidence that CJC-1295 can increase growth hormone and IGF-1. It does not support claims of improved body composition, sleep, recovery, injury healing, or longevity.academic.oup+1
Seredenin, S. B., Kozlovskaya, M. M., et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in generalized anxiety disorder and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, 108(4), 38–48.Supports the small, primarily Russian clinical literature for Selank in anxiety-related conditions. The study should be interpreted cautiously because the evidence has not been established through large, independently replicated, modern placebo-controlled trials.pubmed.ncbi.nlm.nih
Medvedev, A. E., et al. (2020). Functional connectomic approach to studying Selank and Semax effects on the brain. [Neuroimaging study].Supports the existence of small healthy-volunteer neuroimaging research involving Semax and Selank; it does not demonstrate clinical treatment benefit for anxiety, ADHD, mood disorders, cognitive decline, or general cognitive enhancement.pubmed.ncbi.nlm.nih
U.S. Food and Drug Administration. (2026). Drug compounding and the FDA: Questions and answers.Supports the distinction between FDA-approved medicines and compounded products, including the statement that compounded drugs are not FDA-approved.
U.S. Food and Drug Administration. (2026). Understanding the risks of compounded drugs.Supports discussion of concerns related to compounded-product quality, potency, contamination, labeling, dosing, and the absence of the usual FDA premarket review for safety and effectiveness.
U.S. Food and Drug Administration. (2026). July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee.Supports the fact that FDA convened PCAC to consider certain peptide-related bulk substances for possible inclusion on the Section 503A Bulks List. It also supports the distinction between an advisory recommendation and FDA drug approval.fda
U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-approved drug products database.https://www.accessdata.fda.gov/scripts/cder/daf/Supports verification of FDA approval status, labels, approval letters, and drug histories for specific peptide-based medications
Comments